CrisPRO Blog

Insights, news, and research at the intersection of AI and oncology.

Building Brain Metastasis Framework Studying Glioblastoma's (GBM) Trial Failures

Featured Article

Building Brain Metastasis Framework Studying Glioblastoma's (GBM) Trial Failures

Every GBM trial failure carries a failure signature — a specific combination of target validity, delivery architecture, patient selection, and resistance mechanism. The question for each trial is not "did it fail?" but "which failure mode applies, and does that mode exist in the BrM context?"

Read Full Story

Series · 4 parts

Platinum Window Hypothesis

Read in order — each part builds on the last.

  1. Part 1Apr 9, 2026

    Part 1: The Signal We Weren't Looking For: Metformin

    You probably know Metformin as a diabetes drug. Costs $7 to $15 a month at any pharmacy. Been around since the 1950s. About as glamorous as a glass of water. But our engine kept ranking it unusually high for ovarian cancer. The IC50 scores were credible. The mechanism was real. And when we dug into the published literature, we found something that genuinely surprised us.

    Read part 1
  2. Part 2Apr 9, 2026

    Part 2: Who is the system failing most, and why?

    We built a computational engine and pointed it at 427 real ovarian cancer patients. We asked one question: who is the system failing most, and why?

    Read part 2
  3. Part 3Apr 9, 2026

    Part 3: The Clock We Didn't Know Was Running

    Two trials failed last year. Not because the drugs didn't work. Because nobody knew what time it was.

    Read part 3
  4. Part 4Apr 9, 2026

    Part 4: 2,500 Patients Just Told Us The Same Thing

    We took two genes — FAP and CXCL10 — and asked a simple question in each cohort: do patients with FAP below their cohort average and CXCL10 above their cohort average live longer than everyone else?

    Read part 4

Also on the blog

Part 2 — NCT02264678 CAPRI: Ceralasertib + Olaparib and the BRCA resistance problem.

April 19, 2026

Part 2 — NCT02264678 CAPRI: Ceralasertib + Olaparib and the BRCA resistance problem.

**Trial:** NCT02264678 (CAPRI)   **Drugs:** Ceralasertib (ATRi) + Olaparib (PARPi)   **Cancer:** Recurrent high-grade serous ovarian carcinoma (HGSOC)   **Published:** Drew et al., *JCO* 2022   **CrisPRO delta:** **+0.108** ·

Read More
Part 1: Adavosertib — NCT03579316 (CrisPRO, WEE1, and PTEN Loss)

April 18, 2026

Part 1: Adavosertib — NCT03579316 (CrisPRO, WEE1, and PTEN Loss)

**Trial:** NCT03579316 **Drug:** Adavosertib (AZD1775) — WEE1 kinase inhibitor **Combination:** + Gemcitabine **Cancer:** Recurrent/refractory solid tumors (ovarian focus) **Published:** JCO 2023 — PMID referenced in CrisPRO validation run **CrisPRO delta:** **+0.307** — strongest of all 5 validations

Read More